Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II randomized pilot study of deferasirox with or without epoetin alfa in low- and Int-1-risk myelodysplastic syndromes
2013-000981-12Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Exjade monotherapy with Exjade + epoetin alfa (2 arms). Primary endpoint: Primary erythroid response at 12 weeks. Started Jun 2013; status: terminated.
02
Drugs
deferasiroxepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2013-000981-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000981-12.